hpv vaccine vaers

epidemiological studies assessing the risk of gbs following hpv vaccination have been published18 including population cohort studies from denmark and sweden.19 in 2017, in response to an online publication from france suggesting an increased risk,20 a large self-controlled case-series study from the uk was conducted, based on a population where 10.4 million doses were administered. also in 2017, the who commissioned a systematic review of serious adverse events (saes) following hpv vaccines. for all outcomes, the evidence from randomized controlled trials was supported by good quality cohort studies, with no difference in rates of selected saes between exposed and unexposed to hpv vaccine observed. autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in denmark and sweden: cohort study. quadrivalent hpv vaccination and the risk of adverse pregnancy outcomes.

gacvs reviewed data from a recent retrospective cohort study from the french national agency for medicines and health products safety on autoimmune conditions following hpv vaccination.6 this large study of >2 million girls showed a similar incidence in the vaccinated and unvaccinated populations for all conditions studied, with the exception of guillain-barre syndrome where an increased risk was identified, mainly focused within 3 months after vaccination. the circumstances in japan, where the occurrence of chronic pain and other symptoms in some vaccine recipients has led to suspension of the proactive recommendation for routine use of hpv vaccine in the national immunization programme, warrants additional comment. while surveillance data and epidemiologic studies on hpv vaccine have remained reassuring, allegations have continued to surface in the media and elsewhere about the safety of the vaccine. in summary, gacvs was presented with a series of cases of adverse events following administration of the hpv vaccine. autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in denmark and sweden: cohort study. 2009 may;5(5):332-40. full report of gacvs meeting of 11-12 december 2013, published in the who weekly epidemiological record on 14 february 2014

fda and cdc continue to monitor the safety of this vaccine, with the public’s health and safety our top priority. fda and cdc closely monitor the safety of all vaccines through the vaccine adverse event reporting system (vaers). in addition to vaers, cdc has two other systems in place to monitor the safety of all licensed vaccines. fda will provide a future update to information on the number of reports of adverse events and doses distributed.

however, none of the adverse events in the safety review, including syncope and vtes, were reported at rates (number of adverse events/number of doses distributed) greater than expected in a population of this age and gender and with other known contributing factors to these adverse events. in the cdc’s vsd, blood clots have not been found to occur more often than expected after over 450,000 doses of gardasil. fda and cdc have reviewed the reports of gbs that have been submitted to vaers. fda and cdc continue to find that gardasil is a safe and effective vaccine that will potentially benefit the health of millions of women by providing protection against the types of hpv in the vaccine that cause cervical, vulvar and vaginal cancer, genital warts, and other hpv-related genital diseases in females.

have you had a reaction following a vaccination? contact your healthcare provider. report an adverse event using the vaers online form or the downloadable pdf. between , vaers received a total of 275,595 vaccinated alone reports, including 171 for hpv2; from 2006 to 2018, there were 322,932 during 2015 to 2018, a total of 16 621 ae reports following hpv vaccination were reported to vaers. nonserious aes accounted for 95.4% (15 863), related conditions, related conditions.

like any vaccine or medicine, hpv vaccines can cause side effects. the most common side effects reported through cdc’s vaccine adverse event reporting system (vaers) are pain, redness, or swelling in the arm where the vaccine was given, dizziness, syncope (fainting), nausea, and headache. a total of 758 serious health problems that arose after hpv vaccination were reported in vaers during that time. meanwhile, the rate of hpv vaccination primarily aims to protect against cervical, anogenital and oropharyngeal cancers, and high-grade cervical lesions related to hpv the risk of anaphylaxis has been characterized as approximately 1.7 cases per million doses, and syncope was established as a common anxiety or stress-related, .

When you try to get related information on hpv vaccine vaers, you may look for related areas. related conditions.